Where a baby girl is a mother's awful shame
By Gethin Chamberlain,
The Observer
| 11. 23. 2008
The birth of Rekha's second daughter should have been one of the happiest days of her life. Instead, she lay on the bed of her home on the outskirts of Delhi, the newborn child on the floor, screaming in terror as her mother-in-law poured paraffin over her.
This was her punishment, the older woman said, preparing to strike a match: Rekha had failed again to deliver a son and it would be better for everyone if she were dead. Suddenly the door burst open and her neighbours rushed in, roused by the frantic screaming. They bundled Rekha and her daughter out of the house, never to return.
In a country where boys remain prized and having a daughter is considered by many to be a curse, they were lucky. Many are not so fortunate. India has banned pre-natal scanning to determine the sex of a baby and made aborting a child as a result of such a scan punishable with five years in prison. Poster campaigns urge Indians to 'save the girl child'.
Yet the latest birth figures tell a...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...